NCT02751918 2019-11-22Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant CancerBayerPhase 1 Completed65 enrolled